Lineage Cell Therapeutics updates COR1 corneal cell therapy program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
July 13, 2026 8:00 AM EDTCompany Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT
COR1 Aims to Provide an Off the Shelf Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the Companys AlloSCOPE 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation Proprietary Thaw and Inject (TAI) Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced CellsCARLSBAD, Calif.--(BUSINESS... More
